Special Issue

Treatment of Affective Disorders: Adverse Effects, Drug Interactions and Tolerability

Message from the Guest Editor

Effective treatment of affective disorders may be challenging. Up to 40% of depressive patients may not achieve satisfactory response to first-line treatment. and in a one-third of them, drug resistance persists after a number of pharmacological interventions, constituting a serious therapeutic issue. Therefore, treatment frequently requires the use of a combination of drugs belonging to different medication classes. Simultaneous use of two or more drugs poses the risk of interactions. This results in drug toxicity effects, multiplication of adverse effects, decreased tolerability and, importantly, significant risk of non-compliance, treatment discontinuation or lack of functional remission. Another issue is the high comorbidity of somatic diseases and affective disorders, often resulting in the accumulation of side effects and interactions between psychotropics and non-psychiatric drugs. Thus, contraindications resulting from general medical state should also be taken into account. In this Special Issue, our aim will be to focus on those challenging aspects of the treatment of affective disorders-adverse effects, drug interactions, and tolerability.

Guest Editor

Dr. Marcin Siwek

Department of Affective Disorders, Chair of Psychiatry, Jagiellonian University Medical College, Kraków, Poland

Deadline for manuscript submissions

closed (31 May 2023)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/127926

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

